Aurobindo Pharma USA received East Windsor Township Planning Board approval at the Oct. 26 meeting to construct a 567,000-square-foot pharmaceutical, warehouse, distribution and manufacturing center that is expected to generate new tax dollars and approximately 400 to 500 new jobs when fully operational.
The East Windsor project is expected to expand Aurobindo’s New Jersey footprint for manufacturing and warehousing and will be located on Windsor Center Drive, across from Route 133 and near the 43,000 square foot Patscentre building, occupied by another pharmaceutical company. “East Windsor is a great location for this type of company,” said East Windsor Mayor Janice Mironov. “This new acquisition and proposed facility highlights the township’s strong business appeal and the tremendous benefits of this commercial site.”
Aurobindo USA’s Chief Executive Officer Robert Cunard said the proposal got a lot of support from East Windsor officials.
“We look forward to a long and successful collaboration, and becoming a member of the East Windsor business community. East Windsor is a perfect location for Aurobindo’s goal of an expanded U.S. and New Jersey presence,” he said.Headquartered in HITEC City, Hyderabad, India, founded in 1986 and becoming a public company in 1992, Aurobindo has business operations in more than 125 countries around the world. Aurobindo Pharma USA is a generic pharmaceutical manufacturer and distributor and is a wholly owned subsidiary of Aurobindo Pharma Limited, a leading generic pharmaceutical company based in India.
